中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer

文献类型：期刊论文

作者Wang, Wenxian1,2,3; Huang, Zhangzhou4; Yu, Zongyang5; Zhuang, Wu4; Zheng, Weijun6; Cai, Zhijian7; Shi, Lei8; Yu, Xinmin1,2,3; Lou, Guangyuan1,2,3; Hong, Wei1,2,3
刊名FRONTIERS IN ONCOLOGY
出版日期2020-10-09
卷号10
关键词immune checkpoint inhibitor non-small cell lung cancer biomarker chemotherapy lung immune prognostic index
ISSN号2234-943X
DOI10.3389/fonc.2020.572853
通讯作者Chen, Ming(chenming@zjcc.org.cn) ; Song, Zhengbo(songzb1983@163.com)
英文摘要Background Lung immune prognostic index (LIPI) status was recently developed to predict responses to immune checkpoint inhibitor (ICI) treatments. However, it is unclear whether LIPI is a prognostic index for both patients treated with ICI monotherapy and patients treated with ICIs combined with chemotherapy (ICIs CC). Methods This retrospective study established the patterns of LIPI in Chinese patients with advanced non-small cell lung cancer. Lung immune prognostic index based on the derived neutrophil-to-lymphocyte ratio greater than 3 and lactate dehydrogenase greater than the upper limit of normal was developed to characterize good, intermediate, or poor LIPI status. Associations between LIPI status and progression-free survival (PFS) and overall survival (OS) were analyzed. Kaplan-Meier curves and Cox proportional hazards models were used to determine survival differences. Results Three hundred thirty patients were included in this study. Of these patients, 216 received ICI monotherapy and 114 received ICIs CC. A good LIPI status was associated with better PFS (6.1 months vs. 2.3 months vs. 2.1 months, P = 0.023) and OS (24.2 months vs. 14.5 months vs. 9.3 months, P < 0.001) in ICI monotherapy compared to intermediate or poor LIPI status. No differences in PFS (17.9 vs. 9.9 months vs. 7.6 months, P = 0.355, respectively) and OS (P = 0.346) were observed in patients who received ICIs CC. Moreover, we found that patients who had an improved LIPI status compared with the baseline value had a longer PFS with ICI monotherapy and LIPI intermediate status (8.4 months vs. 2.1 months vs. 1.4 months, P < 0.001). However, in patients treated with ICIs CC, these dynamic changes were not observed (P = 0.444). Conclusions Lung immune prognostic index status and dynamic changes in LIPI could be prognostic markers of treatment response to ICI monotherapy, but not to ICIs CC. In particular, good LIPI status was associated with a better clinical outcome compared with intermediate and poor LIPI status in ICI monotherapy treatment.
WOS关键词TO-LYMPHOCYTE RATIO ; SERUM LACTATE-DEHYDROGENASE ; EARLY MARKER ; OPEN-LABEL ; NSCLC ; OUTCOMES ; PEMBROLIZUMAB ; ASSOCIATION ; THERAPY ; IMMUNOTHERAPY
资助项目National Natural Science Foundation of China[81802276]
WOS研究方向Oncology
语种英语
WOS记录号WOS:000581168900001
出版者FRONTIERS MEDIA SA
资助机构National Natural Science Foundation of China
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/104600]  
专题中国科学院合肥物质科学研究院
通讯作者Chen, Ming; Song, Zhengbo
作者单位1.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
2.Zhejiang Canc Hosp, Hangzhou, Peoples R China
3.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China
4.Fujian Med Univ, Fujian Prov Canc Hosp, Dept Med Oncol, Canc Hosp, Fuzhou, Peoples R China
5.900th Hosp, Dept Med Oncol, Fuzhou, Peoples R China
6.Zhejiang Chinese Med Sch, Coll Publ Hlth, Dept Med Stat, Hangzhou, Peoples R China
7.Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou, Peoples R China
8.Hangzhou YITU Healthcare Technol Co Ltd, Hangzhou, Peoples R China
9.Zhejiang Canc Hosp, Zhejiang Key Lab Radiat Oncol, Hangzhou, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Wenxian,Huang, Zhangzhou,Yu, Zongyang,et al. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer[J]. FRONTIERS IN ONCOLOGY,2020,10.
APA Wang, Wenxian.,Huang, Zhangzhou.,Yu, Zongyang.,Zhuang, Wu.,Zheng, Weijun.,...&Song, Zhengbo.(2020).Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.FRONTIERS IN ONCOLOGY,10.
MLA Wang, Wenxian,et al."Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer".FRONTIERS IN ONCOLOGY 10(2020).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。